CONMED Corporation (CNMD)
| Market Cap | 1.51B +11.8% |
| Revenue (ttm) | 1.37B +1.6% |
| Net Income | 73.43M +14.6% |
| EPS | 2.41 +17.5% |
| Shares Out | 29.80M |
| PE Ratio | 21.01 |
| Forward PE | 10.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,711 |
| Open | 51.45 |
| Previous Close | 50.48 |
| Day's Range | 50.40 - 51.45 |
| 52-Week Range | 31.44 - 54.80 |
| Beta | 0.89 |
| Analysts | Hold |
| Price Target | 46.83 (-7.43%) |
| Earnings Date | Oct 28, 2026 |
About CNMD
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products... [Read more]
Financial Performance
In 2025, CONMED's revenue was $1.37 billion, an increase of 5.18% compared to the previous year's $1.31 billion. Earnings were $47.06 million, a decrease of -64.47%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CNMD stock is "Hold." The 12-month stock price target is $46.83, which is a decrease of -7.43% from the latest price.
News
CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Jefferies Global Healthcare Conference, which is being held November 16-19, 2026 at the Waldorf H...
Conmed price target raised to $50 from $45 at JPMorgan
JPMorgan raised the firm’s price target on Conmed (CNMD) to $50 from $45 and keeps a Neutral rating on the shares.
Conmed reports Q3 EPS $1.04, consensus $1.00
Reports Q3 revenue $335.6M, consensus $336.3M. “Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflectin...
Conmed raises FY26 EPS view to $4.54-$4.61 from $4.48-$4.60, consensus $4.54
Narrows FY26 revenue view to $1.36B-$1.366B from $1.358B-$1.373B
CONMED Earnings Call Transcript: Q3 2026
Q3 organic constant-currency revenue grew 6.7%, with adjusted EPS of $1.04 exceeding expectations. FY 2026 organic growth guidance narrowed to 5.0%–5.5%, while adjusted EPS guidance rose to $4.54–$4.61.
CONMED Earnings release: Q3 2026
CONMED released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
CONMED Quarterly report: Q3 2026
CONMED has published its Q3 2026 quarterly earnings report on October 28, 2026.
CONMED Slides: Q3 2026
CONMED has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year endin...
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. Th...
CONMED Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted accelerated growth driven by strong performance in minimally invasive surgery and sports medicine, with AirSeal, BioBrace, and Buffalo Filter as key growth drivers. International expansion, margin improvement, and ongoing investment in sales and R&D support the outlook, while tuck-in M&A remains a strategic priority.
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the En...
Conmed price target raised to $45 from $40 at JPMorgan
JPMorgan raised the firm’s price target on Conmed (CNMD) to $45 from $40 and keeps a Neutral rating on the shares.
Conmed price target raised to $45 from $39 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Conmed (CNMD) to $45 from $39 and keeps a Neutral rating on the shares. The firm notes the company…
CONMED Earnings Call Transcript: Q2 2026
Q2 2026 saw 6% organic sales growth, strong EPS, and margin expansion, driven by AirSeal, Buffalo Filter, and BioBrace. Guidance for 2026 was raised for EPS but narrowed for sales growth, with continued operational and leadership enhancements.
CONMED Earnings release: Q2 2026
CONMED released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
CONMED Slides: Q2 2026
CONMED has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
CONMED Quarterly report: Q2 2026
CONMED has published its Q2 2026 quarterly earnings report on July 29, 2026.
Conmed reports Q2 adjusted EPS $1.38, consensus $1.11
Reports Q2 rervenue $343.5M, consensus $337.54M. “We delivered a strong second quarter, with organic constant currency net sales growth and adjusted diluted EPS that exceeded our stated expectations,”...
Conmed raises FY26 EPS view to $4.48-$4.60 from $4.30-$4.45, consensus $4.34
Raises FY26 revenue view to $1.358B-$1.373B from $1.35B-$1.375B, consensus $1.36B.
CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 20...
Conmed announces expanded indication for AirSeal Robotic Solution
CONMED (CNMD) Corporation announced that its AirSeal Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform.
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive's 8 mm hex cannulas used as part of the Intuiti...
Conmed to present data from randomized controlled clinical trial at SRS meeting
CONMED (CNMD) Corporation announced its participation in the Society of Robotic Surgery 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor…
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in For...